Host response to nontuberculous mycobacterial infections of current clinical importance

Infection and Immunity

Volumn 82, Issue 9, 2014, Pages 3516-3522

  Orme, Ian M ^a   Ordway, Diane J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIAL IMMUNITY; BACTERIAL LOAD; CLINICAL FEATURE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INCIDENCE; MOLECULAR ECOLOGY; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM ABSCESSUS; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; HUMANS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS;

EID: 84906052544     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01606-13     Document Type: Short Survey

References (87)

1. Falkinham JO, III. 2013. Ecology of nontuberculous mycobacteria-where do human infections come from? Semin. Respir. Crit. Care Med. 34:95-102. http://dx.doi.org/10.1055/s-0033-1333568.
2. McGrath EE, Blades Z, McCabe J, Jarry H, Anderson PB. 2010. Nontuberculous mycobacteria and the lung: from suspicion to treatment. Lung 188:269-282. http://dx.doi.org/10.1007/s00408-010-9240-9.
3. van Ingen J, Blaak H, de Beer J, de Roda Husman AM, van Soolingen D. 2010. Rapidly growing nontuberculous mycobacteria cultured from home tap and shower water. Appl. Environ. Microbiol. 76:6017-6019. http://dx.doi.org/10.1128/AEM.00843-10.
4. Hernández-Garduño E, Elwood K. 2012. Nontuberculous mycobacteria in tap water. Emerg. Infect. Dis. 18:353. http://dx.doi.org/10.3201/eid1802.110455.
5. Falkinham JO, III. 2009. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J. Appl. Microbiol. 107:356-367. http://dx.doi.org/10.1111/j.1365-2672.2009.04161.x.
6. van der Wielen PW, van der Kooij D. 2013. Nontuberculous mycobacteria, fungi, and opportunistic pathogens in unchlorinated drinking water in The Netherlands. Appl. Environ. Microbiol. 79:825-834. http://dx.doi.org/10.1128/AEM.02748-12.
7. Behr MA, Falkinham JO, III. 2009. Molecular epidemiology of nontuberculous mycobacteria. Future Microbiol. 4:1009-1020. http://dx.doi.org/10.2217/fmb.09.75.
8. Falkinham JO, III. 2011. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg. Infect. Dis. 17:419-424. http://dx.doi.org/10.3201/eid1703.101510.
9. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, Peacock SJ, Parkhill J, Floto RA. 2013. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 381:1551-1560. http://dx.doi.org/10.1016/S0140-6736(13)60632-7.
10. Falkinham JO. 2010. Impact of human activities on the ecology of nontuberculous mycobacteria. Future Microbiol. 5:951-960. http://dx.doi.org/10.2217/fmb.10.53.
11. Orme IM, Roberts AD, Furney SK, Skinner PS. 1994. Animal and cell-culture models for the study of mycobacterial infections and treatment. Eur. J. Clin. Microbiol. Infect. Dis. 13:994-999. http://dx.doi.org/10.1007/BF02111500.
12. Orme IM. 2014. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis (Edinb.) 94:8-14. http://dx.doi.org/10.1016/j.tube.2013.07.004.
13. Williams MM, Yakrus MA, Arduino MJ, Cooksey RC, Crane CB, Banerjee SN, Hilborn ED, Donlan RM. 2009. Structural analysis of biofilm formation by rapidly and slowly growing nontuberculous mycobacteria. Appl. Environ. Microbiol. 75:2091-2098. http://dx.doi.org/10.1128/AEM.00166-09.
14. Weiss CH, Glassroth J. 2012. Pulmonary disease caused by nontuberculous mycobacteria. Exp. Rev. Respir. Med. 6:597-612. http://dx.doi.org/10.1586/ers.12.58.
15. Glazer CS, Martyny JW, Lee B, Sanchez TL, Sells TM, Newman LS, Murphy J, Heifets L, Rose CS. 2007. Nontuberculous mycobacteria in aerosol droplets and bulk water samples from therapy pools and hot tubs. J. Occup. Environ. Hyg. 4:831-840. http://dx.doi.org/10.1080/15459620701634403.
16. Pinto-Powell R, Olivier KN, Marsh BJ, Donaldson S, Parker HW, Boyle W, Knowles M, Magnusson M, von Reyn CF. 1996. Skin testing with Mycobacterium avium sensitin to identify infection with M. avium complex in patients with cystic fibrosis. Clin. Infect. Dis. 22:560-562. http://dx.doi.org/10.1093/clinids/22.3.560.
17. Leung JM, Olivier KN. 2013. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin. Respir. Crit. Care Med. 34:124-134. http://dx.doi.org/10.1055/s-0033-1333574.
18. Hoefsloot W, van Ingen J, Magis-Escurra C, Reijers MH, van Soolingen D, Dekhuijzen RP, Boeree MJ. 2013. Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations. J. Infect. 66:542-545. http://dx.doi.org/10.1016/j.jinf.2012.12.011.
19. Brown-Elliott BA, Nash KA, Wallace RJ, Jr. 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev. 25:545-582. http://dx.doi.org/10.1128/CMR.05030-11.
20. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. 2012. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Updat. 15:149-161. http://dx.doi.org/10.1016/j.drup.2012.04.001.
21. Ordway DJ, Shanley CA, Caraway ML, Orme EA, Bucy DS, Hascall-Dove L, Henao-Tamayo M, Harton MR, Shang S, Ackart D, Kraft SL, Lenaerts AJ, Basaraba RJ, Orme IM. 2010. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob. Agents Chemother. 54:1820-1833. http://dx.doi.org/10.1128/AAC.01521-09.
22. Stout JE, Floto RA. 2012. Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others. Am. J. Respir. Crit. Care Med. 186:822-823. http://dx.doi.org/10.1164/rccm.201208-1500ED.
23. Bermudez LE, Inderlied CB, Young LS. 1992. Mycobacterium avium complex in AIDS. Curr. Clin. Top. Infect. Dis. 12:257-281.
24. Epson E, Cassidy M, Marshall-Olson A, Hedberg K, Winthrop KL. 2012. Patients with nontuberculous mycobacteria: comparison of updated and previous diagnostic criteria for lung disease. Diagn. Microbiol. Infect. Dis. 74:98-100. http://dx.doi.org/10.1016/j.diagmicrobio.2012.05.035.
25. Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, Yang PC, Luh KT, Hsueh PR. 2010. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg. Infect. Dis. 16:294-296. http://dx.doi.org/10.3201/eid1602.090675.
26. Al Houqani M, Jamieson F, Chedore P, Mehta M, May K, Marras TK. 2011. Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can. Respir. J. 18:19-24. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071009/pdf/crj18019.pdf.
27. Chen CY, Chen HY, Chou CH, Huang CT, Lai CC, Hsueh PR. 2012. Pulmonary infection caused by nontuberculous mycobacteria in a medical center in Taiwan, 2005-2008. Diagn. Microbiol. Infect. Dis. 72:47-51. http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.009.
28. Kurahara Y, Tachibana K, Tsuyuguchi K, Suzuki K. 2013. Mixed pulmonary infection with three types of nontuberculous mycobacteria. Intern. Med. 52:507-510. http://dx.doi.org/10.2169/internalmedicine.52.8907.
29. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Dasa R, Daley CL, Dekhuijzen PN, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, Gomez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R, Mannsaker T, Marras TK, Maugein J, Milburn HJ, Mlinko T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Pena M, Piersimoni C, Polanova M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szabo N, Thomson R, Fernandez MT, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop K, Wagner D. 2013. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: A NTM-NET collaborative study. Eur. Respir. J. 42:1604-1613. http://dx.doi.org/10.1183/09031936.00149212.
30. Cook JL. 2010. Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts. Br. Med. Bull. 96:45-59. http://dx.doi.org/10.1093/bmb/ldq035.
31. Winthrop KL. 2010. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view. Future Microbiol. 5:343-345. http://dx.doi.org/10.2217/fmb.10.13.
32. Thomson RM. 2010. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg. Infect. Dis. 16:1576-1583. http://dx.doi.org/10.3201/eid1610.091201.
33. Jang MA, Kim SY, Jeong BH, Park HY, Jeon K, Kim JW, Ki CS, Koh WJ. 2013. Association of CFTR gene variants with nontuberculous mycobacterial lung disease in a Korean population with a low prevalence of cystic fibrosis. J. Hum. Genet. 58:298-303. http://dx.doi.org/10.1038/jhg.2013.19.
34. Chan ED, Bai X, Kartalija M, Orme IM, Ordway DJ. 2010. Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am. J. Respir. Cell Mol. Biol. 43:387-393. http://dx.doi.org/10.1165/rcmb.2009-0276TR.
35. Orme IM, Collins FM. 1983. Resistance of various strains of mycobacteria to killing by activated macrophages in vivo. J. Immunol. 131:1452-1454.
36. Orme IM, Collins FM. 1986. Crossprotection against nontuberculous mycobacterial infections by Mycobacterium tuberculosis memory immune T lymphocytes. J. Exp. Med. 163:203-208. http://dx.doi.org/10.1084/jem.163.1.203.
37. Orme IM, Collins FM. 1984. Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect. Immun. 44:28-32.
38. Orme IM, Stokes RW, Collins FM. 1986. Genetic control of natural resistance to nontuberculous mycobacterial infections in mice. Infect. Immun. 54:56-62.
39. Young LS, Bermudez LE. 2001. Perspective on animal models: chronic intracellular infections. Clin. Infect. Dis. 33(Suppl 3):S221-S226. http://dx.doi.org/10.1086/321851.
40. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. 1992. An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract. J. Infect. Dis. 165:75-79. http://dx.doi.org/10.1093/infdis/165.1.75.
41. Sangari FJ, Goodman J, Petrofsky M, Kolonoski P, Bermudez LE. 2001. Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes. Infect. Immun. 69:1515-1520. http://dx.doi.org/10.1128/IAI.69.3.1515-1520.2001.
42. Bermudez LE, Young LS. 1988. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J. Immunol. 140:3006-3013.
43. Furney SK, Skinner PS, Roberts AD, Appelberg R, Orme IM. 1992. Capacity of Mycobacterium avium isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor. Infect. Immun. 60:4410-4413.
44. Bermudez LE, Young LS. 1989. Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex. Microb. Pathog. 7:289-298. http://dx.doi.org/10.1016/0882-4010(89)90047-8.
45. Pedrosa J, Flórido M, Kunze ZM, Castro AG, Portaels F, McFadden J, Silva MT, Appelberg R. 1994. Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice. Clin. Exp. Immunol. 98:210-216.
46. Appelberg R. 1994. Protective role of interferon gamma, tumor necrosis factor alpha and interleukin-6 in Mycobacterium tuberculosis and M. avium infections. Immunobiology 191:520-525. http://dx.doi.org/10.1016/S0171-2985(11)80458-4.
47. Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minoprio P. 1994. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and-dependent phases of Mycobacterium avium infection. Infect. Immun. 62:3962-3971.
48. Castro AG, Silva RA, Appelberg R. 1995. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J. Immunol. 155:2013-2019.
49. Bermudez LE, Wu M, Young LS. 1995. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect. Immun. 63:4099-4104.
50. Appelberg R, Castro AG, Pedrosa J, Minoprio P. 1994. Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice. Immunology 82:361-364.
51. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. 2009. Nontuberculous mycobacteria infections and anti-tumor necrosis factoralpha therapy. Emerg. Infect. Dis. 15:1556-1561. http://dx.doi.org/10.3201/eid1510.090310.
52. Swart RM, van Ingen J, van Soolingen D, Slingerland R, Hendriks WD, den Hollander JG. 2009. Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists. Emerg. Infect. Dis. 15:1700-1701. http://dx.doi.org/10.3201/eid1510.090110.
53. Appelberg R, Pedrosa J. 1992. Induction and expression of protective T cells during Mycobacterium avium infections in mice. Clin. Exp. Med. 87:379-385.
54. Orme IM. 1988. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 56:3310-3312.
55. Hubbard RD, Flory CM, Collins FM. 1992. T-cell immune responses in Mycobacterium avium-infected mice. Infect. Immun. 60:150-153.
56. Appelberg R, Castro AG, Gomes S, Pedrosa J, Silva MT. 1995. Susceptibility of beige mice to Mycobacterium avium: role of neutrophils. Infect. Immun. 63:3381-3387.
57. Gonçalves AS, Appelberg R. 2002. The involvement of the chemokine receptor CXCR2 in neutrophil recruitment in LPS-induced inflammation and in Mycobacterium avium infection. Scand. J. Immunol. 55:585-591. http://dx.doi.org/10.1046/j.1365-3083.2002.01097.x.
58. Gomes MS, Flórido M, Pais TF, Appelberg R. 1999. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J. Immunol. 162:6734-6739.
59. Flórido M, Gonçalves AS, Silva RA, Ehlers S, Cooper AM, Appelberg R. 1999. Resistance of virulent Mycobacterium avium to gamma interferonmediated antimicrobial activity suggests additional signals for induction of mycobacteriostasis. Infect. Immun. 67:3610-3618.
60. Lousada S, Flórido M, Appelberg R. 2006. Regulation of granuloma fibrosis by nitric oxide during Mycobacterium avium experimental infection. Int. J. Exp. Pathol. 87:307-315. http://dx.doi.org/10.1111/j.1365-2613.2006.00487.x.
61. Ehlers S, Kutsch S, Benini J, Cooper A, Hahn C, Gerdes J, Orme I, Martin C, Rietschel ET. 1999. NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 98: 313-323. http://dx.doi.org/10.1046/j.1365-2567.1999.00875.x.
62. Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K. 1999. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect. Immun. 67:3571-3579.
63. Flórido M, Appelberg R. 2004. Granuloma necrosis during Mycobacterium avium infection does not require tumor necrosis factor. Infect. Immun. 72:6139-6141. http://dx.doi.org/10.1128/IAI.72.10.6139-6141.2004.
64. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, Andersen P. 2002. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70:672-678. http://dx.doi.org/10.1128/IAI.70.2.672-678.2002.
65. Rook GA, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR. 2004. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Sem. Immunopathol. 25:237-255. http://dx.doi.org/10.1007/s00281-003-0148-9.
66. Andersen P, Doherty TM. 2005. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3:656-662. http://dx.doi.org/10.1038/nrmicro1211.
67. Lin MY, Reddy TB, Arend SM, Friggen AH, Franken KL, van Meijgaarden KE, Verduyn MJ, Schoolnik GK, Klein MR, OttenhoffTH. 2009. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect. Immun. 77:5071-5079. http://dx.doi.org/10.1128/IAI.00457-09.
68. Bermudez LE, Wu M, Miltner E, Inderlied CB. 1999. Isolation of two subpopulations of Mycobacterium avium within human macrophages. FEMS Microbiol. Lett. 178:19-26. http://dx.doi.org/10.1016/S0378-1097(99)00331-6.
69. Carter G, Wu M, Drummond DC, Bermudez LE. 2003. Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J. Med. Microbiol. 52:747-752. http://dx.doi.org/10.1099/jmm.0.05224-0.
70. Li YJ, Danelishvili L, Wagner D, Petrofsky M, Bermudez LE. 2010. Identification of virulence determinants of Mycobacterium avium that impact on the ability to resist host killing mechanisms. J. Med. Microbiol. 59:8-16. http://dx.doi.org/10.1099/jmm.0.012864-0.
71. Gomes MS, Flórido M, Cordeiro JV, Teixeira CM, Takeuchi O, Akira S, Appelberg R. 2004. Limited role of the Toll-like receptor-2 in resistance to Mycobacterium avium. Immunology 111:179-185. http://dx.doi.org/10.1111/j.0019-2805.2003.01807.x.
72. Sampaio EP, Elloumi HZ, Zelazny A, Ding L, Paulson ML, Sher A, Bafica AL, Shea YR, Holland SM. 2008. Mycobacterium abscessus and M. avium trigger Toll-like receptor 2 and distinct cytokine response in human cells. Am. J. Respir. Cell Mol. Biol. 39:431-439. http://dx.doi.org/10.1165/rcmb.2007-0413OC.
73. Briken V, Ahlbrand SE, Shah S. 2013. Mycobacterium tuberculosis and the host cell inflammasome: a complex relationship. Front. Cell. Infect. Biol. 3:62. http://dx.doi.org/10.3389/fcimb.2013.00062.
74. Flórido M, Pearl JE, Solache A, Borges M, Haynes L, Cooper AM, Appelberg R. 2005. Gamma interferon-induced T-cell loss in virulent Mycobacterium avium infection. Infect. Immun. 73:3577-3586. http://dx.doi.org/10.1128/IAI.73.6.3577-3586.2005.
75. Cooper AM, Appelberg R, Orme IM. 1998. Immunopathogenesis of Mycobacterium avium infection. Front. Biosci. 3:e141-e148.
76. Appelberg R. 2006. Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium? Immunol. Res. 35:179-190. http://dx.doi.org/10.1385/IR:35:3:179.
77. Rocco JM, Irani VR. 2011. Mycobacterium avium and modulation of the host macrophage immune mechanisms. Int. J. Tuberc. Lung Dis. 15:447-452. http://dx.doi.org/10.5588/ijtld.09.0695.
78. Ordway D, Henao-Tamayo M, Smith E, Shanley C, Harton M, Troudt J, Bai X, Basaraba RJ, Orme IM, Chan ED. 2008. Animal model of Mycobacterium abscessus lung infection. J. Leukoc. Biol. 83:1502-1511. http://dx.doi.org/10.1189/jlb.1007696.
79. Byrd TF, Lyons CR. 1999. Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect. Immun. 67:4700-4707.
80. Howard ST, Rhoades E, Recht J, Pang X, Alsup A, Kolter R, Lyons CR, Byrd TF. 2006. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 152:1581-1590. http://dx.doi.org/10.1099/mic.0.28625-0.
81. Rottman M, Catherinot E, Hochedez P, Emile JF, Casanova JL, Gaillard JL, Soudais C. 2007. Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice. Infect. Immun. 75:5898-5907. http://dx.doi.org/10.1128/IAI.00014-07.
82. Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile JF, Daffe M, Perronne C, Soudais C, Gaillard JL, Rottman M. 2007. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect. Immun. 75:1055-1058. http://dx.doi.org/10.1128/IAI.00835-06.
83. Catherinot E, Roux AL, Macheras E, Hubert D, Matmar M, Dannhoffer L, Chinet T, Morand P, Poyart C, Heym B, Rottman M, Gaillard JL, Herrmann JL. 2009. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J. Clin. Microbiol. 47:271-274. http://dx.doi.org/10.1128/JCM.01478-08.
84. Rhoades ER, Archambault AS, Greendyke R, Hsu FF, Streeter C, Byrd TF. 2009. Mycobacterium abscessus glycopeptidolipids mask underlying cell wall phosphatidyl-myo-inositol mannosides blocking induction of human macrophage TNF-alpha by preventing interaction with TLR2. J. Immunol. 183:1997-2007. http://dx.doi.org/10.4049/jimmunol.0802181.
85. Davidson LB, Nessar R, Kempaiah P, Perkins DJ, Byrd TF. 2011. Mycobacterium abscessus glycopeptidolipid prevents respiratory epithelial TLR2 signaling as measured by HbetaD2 gene expression and IL-8 release. PLoS One 6(12):e29148. http://dx.doi.org/10.1371/journal.pone.0029148.
86. Nessar R, Reyrat JM, Davidson LB, Byrd TF. 2011. Deletion of the mmpL4b gene in the Mycobacterium abscessus glycopeptidolipid biosynthetic pathway results in loss of surface colonization capability, but enhanced ability to replicate in human macrophages and stimulate their innate immune response. Microbiology 157:1187-1195. http://dx.doi.org/10.1099/mic.0.046557-0.
87. Roux AL, Ray A, Pawlik A, Medjahed H, Etienne G, Rottman M, Catherinot E, Coppee JY, Chaoui K, Monsarrat B, Toubert A, Daffe M, Puzo G, Gaillard JL, Brosch R, Dulphy N, Nigou J, Herrmann JL. 2011. Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants. Cell. Microbiol. 13:692-704. http://dx.doi.org/10.1111/j.1462-5822.2010.01565.x.